These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 17728214)

  • 41. [Examination of factors affecting adverse reactions and dosage reduction in UGT1A1 genotyped patients: a retrospective survey of irinotecan].
    Okazaki K; Watanabe T; Saito I; Murayama J
    Yakugaku Zasshi; 2012; 132(2):231-6. PubMed ID: 22293705
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase I study of irinotecan for previously treated lung cancer patients with the UGT1A1*28 or *6 polymorphism: Results of the Lung Oncology Group in Kyushu (LOGIK1004A).
    Fukuda M; Shimada M; Kitazaki T; Nagashima S; Hashiguchi K; Ebi N; Takayama K; Nakanishi Y; Semba H; Harada T; Seto T; Okamoto I; Ichinose Y; Sugio K
    Thorac Cancer; 2017 Jan; 8(1):40-45. PubMed ID: 27883280
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The power of genes: a case of unusually severe systemic toxicity after localized hepatic chemoembolization with irinotecan-eluted microspheres for metastatic colon cancer.
    Cruz JE; Saksena R; Jabbour SK; Nosher JL; Hermes-DeSantis E; Moss RA
    Ann Pharmacother; 2014 Dec; 48(12):1646-50. PubMed ID: 25202035
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Invader UGT1A1 molecular assay for irinotecan toxicity. A genetic test for an increased risk of toxicity from the cancer chemotherapy drug irinotecan (Camptosar).
    Med Lett Drugs Ther; 2006 May; 48(1234):39-40. PubMed ID: 16685247
    [No Abstract]   [Full Text] [Related]  

  • 45. Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review.
    Palomaki GE; Bradley LA; Douglas MP; Kolor K; Dotson WD
    Genet Med; 2009 Jan; 11(1):21-34. PubMed ID: 19125129
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Association of UGT1A1 (*28, *60 and * 93) polymorphism with the adverse reactions of irinotecan chemotherapy in extensive stage small cell lung cancer].
    Ma L; Chen Y; Yang C; Jiang H; Zhu J; Cheng Y
    Zhonghua Zhong Liu Za Zhi; 2015 Jan; 37(1):29-32. PubMed ID: 25877315
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Associations between UGT1A1*6/*28 polymorphisms and irinotecan-induced severe toxicity in Chinese gastric or esophageal cancer patients.
    Gao J; Zhou J; Li Y; Peng Z; Li Y; Wang X; Shen L
    Med Oncol; 2013; 30(3):630. PubMed ID: 23783485
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of Shengjiangxiexin decoction on irinotecan-induced toxicity in patients with UGT1A1*28 and UGT1A1*6 polymorphisms.
    Deng B; Jia L; Tan H; Lou Y; Li X; Li Y; Yu L
    J Tradit Chin Med; 2017 Feb; 37(1):35-42. PubMed ID: 29956901
    [TBL] [Abstract][Full Text] [Related]  

  • 49. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity.
    Iyer L; Das S; Janisch L; Wen M; Ramírez J; Karrison T; Fleming GF; Vokes EE; Schilsky RL; Ratain MJ
    Pharmacogenomics J; 2002; 2(1):43-7. PubMed ID: 11990381
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses.
    Campbell JM; Stephenson MD; Bateman E; Peters MD; Keefe DM; Bowen JM
    Pharmacogenomics J; 2017 Jan; 17(1):21-28. PubMed ID: 27503581
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Associations between UGT1A1*6 or UGT1A1*6/*28 polymorphisms and irinotecan-induced neutropenia in Asian cancer patients.
    Han FF; Guo CL; Yu D; Zhu J; Gong LL; Li GR; Lv YL; Liu H; An GY; Liu LH
    Cancer Chemother Pharmacol; 2014 Apr; 73(4):779-88. PubMed ID: 24519753
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Study of irinotecan-induced toxicity and its correlation to UGT1A1 gene promoter polymorphisms].
    Li H; Huang H; Liu JH
    Zhonghua Fu Chan Ke Za Zhi; 2011 Dec; 46(12):888-91. PubMed ID: 22333276
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacogenetic approach for cancer treatment-tailored medicine in practice.
    Hasegawa Y; Ando Y; Ando M; Hashimoto N; Imaizumi K; Shimokata K
    Ann N Y Acad Sci; 2006 Nov; 1086():223-32. PubMed ID: 17185519
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein.
    de Jong FA; Scott-Horton TJ; Kroetz DL; McLeod HL; Friberg LE; Mathijssen RH; Verweij J; Marsh S; Sparreboom A
    Clin Pharmacol Ther; 2007 Jan; 81(1):42-9. PubMed ID: 17185998
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase II and UGT1A1 genotype study of irinotecan dose escalation as salvage therapy for advanced gastric cancer.
    Jo JC; Lee JL; Ryu MH; Chang HM; Kim M; Lee HJ; Kim HS; Shin JG; Kim TW; Kang YK
    Br J Cancer; 2012 May; 106(10):1591-7. PubMed ID: 22516947
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
    Genet Med; 2009 Jan; 11(1):15-20. PubMed ID: 19125128
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Importance of UDP-glucuronosyltransferase 1A1*6 for irinotecan toxicities in Japanese cancer patients.
    Sai K; Saito Y; Sakamoto H; Shirao K; Kurose K; Saeki M; Ozawa S; Kaniwa N; Hirohashi S; Saijo N; Sawada J; Yoshida T
    Cancer Lett; 2008 Mar; 261(2):165-71. PubMed ID: 18082937
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer.
    Toffoli G; Cecchin E; Corona G; Russo A; Buonadonna A; D'Andrea M; Pasetto LM; Pessa S; Errante D; De Pangher V; Giusto M; Medici M; Gaion F; Sandri P; Galligioni E; Bonura S; Boccalon M; Biason P; Frustaci S
    J Clin Oncol; 2006 Jul; 24(19):3061-8. PubMed ID: 16809730
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prolonged neutropenia after irinotecan-based chemotherapy in a child with polymorphisms of UGT1A1 and SLCO1B1.
    Sakaguchi S; Garcia-Bournissen F; Kim R; Schwarz UI; Nathan PC; Ito S
    Arch Dis Child; 2009 Dec; 94(12):981-2. PubMed ID: 19608554
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Life-threatening toxicities in a patient with UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes after irinotecan-based chemotherapy.
    Takane H; Kawamoto K; Sasaki T; Moriki K; Moriki K; Kitano H; Higuchi S; Otsubo K; Ieiri I
    Cancer Chemother Pharmacol; 2009 May; 63(6):1165-9. PubMed ID: 18998132
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.